STRATA Skin Sciences, Inc. Stock BOERSE MUENCHEN

Equities

E2O

US86272A3059

Advanced Medical Equipment & Technology

Market Closed - BOERSE MUENCHEN 09:13:33 2024-06-17 am EDT 5-day change 1st Jan Change
2.8 EUR -17.65% Intraday chart for STRATA Skin Sciences, Inc. 0.00% 0.00%
Sales 2024 * 31.16M 29.09M Sales 2025 * 33.82M 31.57M Capitalization 10.76M 10.05M
Net income 2024 * -10M -9.34M Net income 2025 * -5M -4.67M EV / Sales 2024 * 0.35 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.32 x
P/E ratio 2024 *
-1.1 x
P/E ratio 2025 *
-1.98 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.41%
More Fundamentals * Assessed data
Dynamic Chart
Current month-23.08%
1 month-21.79%
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 18-04-09
Director of Finance/CFO 42 21-07-05
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 56 18-05-28
Chief Executive Officer 60 18-04-09
Director/Board Member 60 18-05-28
More insiders
STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.07 USD
Average target price
26 USD
Spread / Average Target
+746.91%
Consensus